Mainz Biomed Stock Forum

$Mainz Biomed (MYNZ.US)$ $Kaixin Holdings (KXIN.US)$ $Haoxi Health Technology (HAO.US)$ $BAIYU Holdings (BYU.US)$ $Interactive Strength (TRNR.US)$ $Fangdd Network (DUO.US)$ $Jet.AI (JTAI.US)$ $Wheeler Real Estate Investment Trust Inc (WHLR.US)$ $Crown Electrokinetics (CRKN.US)$ $BloomZ (BLMZ.US)$ $Tevogen Bio Holdings (TVGN.US)$
📊⚡️📊

$Mainz Biomed (MYNZ.US)$  w subpar volume not bad today. tomorrow we will see over .308 and next resitance after that is .325. im thinking big bullish! whats you guys thoughts?

$Mainz Biomed (MYNZ.US)$
Guys , the rate cut has already been confirmed. I suggest you hold your stock instead of selling them cheap

$Mainz Biomed (MYNZ.US)$  presents a significant opportunity for substantial profits, driven by several key catalysts. First, we anticipate an upcoming announcement regarding FDA clearance for a breakthrough device, followed by FDA approval within the next 30 days. This is an opportune moment to consider purchasing shares.

$Mainz Biomed (MYNZ.US)$ Companies that have partnered or collaborated with Mainz Biomed till the latest update:
1. **GANZIMMUN Diagnostics** (Germany) – Commercialization and distribution of ColoAlert [oai_citation:6,Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy - Mainz Biomed](https://mainzbiomed.com/mainz-biomed-establishes-strategic-partnership-with-tomalab-to-expand-availability-of-coloalert-in-italy/).
2. **testDNA Laboratory** (P...

$Mainz Biomed (MYNZ.US)$ Mainz Biomed’s **next-generation multimodal screening test** has been under development and recently made significant progress. The test has shown strong performance in various clinical trials, including **ColoFuture** and **eAArly Detect** studies. It integrates the **Fecal Immunochemical Test (FIT)** with proprietary **mRNA biomarkers** and advanced **AI/machine learning** algorithms, offering a more comprehensive approach to colorectal cancer screening [oai_citation:10...

$Mainz Biomed (MYNZ.US)$ Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
2 minutes ago, 4:01 AM EDT
Via GlobeNewswire

$Mainz Biomed (MYNZ.US)$
The untapped market size for early detection of colorectal cancer in the U.S. is significant. According to various sources, approximately one-third of U.S. residents aged 50-75 have never been screened for colon cancer. This represents a considerable gap in the market, especially given that colorectal cancer is the third most common cancer globally.
Specifically, this gap in screening translates into a market opportunity estimated to be over $4 billion annually. This figu...

$Mainz Biomed (MYNZ.US)$ FDA usually decides on applications for Breakthrough Devices within 60 days. Thus, the decision should be out by 9 Sept.

$Mainz Biomed (MYNZ.US)$
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
Mainz Biomed N.V. (NASDAQ: MYNZ) has announced significant improvements to its ColoAlert product, a highly efficacious at-home detection test for colorectal cancer (CRC). The enhancements include:
1. A novel DNA stabilizing buffer that accommodates varying sample volumes, reducing the need for retesting and enabling results delivery within 2-3 days...